99465-09-5

Basic information

• Product Name: 5-BROMO-1H-QUINOLIN-2-ONE
• Synonyms: 5-BROMO-1H-QUINOLIN-2-ONE;5-BROMOQUINOLIN-2(1H)-ONE;5-Bromoquinolin-2(1H)-on
• CAS NO: 99465-09-5
• Molecular Formula: C₉H₆BrNO
• Molecular Weight: 224.056
• Mol File: 99465-09-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-BROMO-1H-QUINOLIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1H-QUINOLIN-2-ONE(99465-09-5)
• EPA Substance Registry System: 5-BROMO-1H-QUINOLIN-2-ONE(99465-09-5)

Safety Data

• Hazardous Substances Data: 99465-09-5(Hazardous Substances Data)

Usage

General Description

5-Bromo-1H-quinolin-2-one is an organic compound with the chemical formula C9H5BrNO. It is a quinolinone derivative that contains a bromine atom at the 5-position. 5-BROMO-1H-QUINOLIN-2-ONE has potential applications in pharmaceutical and agrochemical industries, as it can be used as a building block in the synthesis of various biologically active compounds. It also exhibits antimicrobial and antifungal properties, making it a potential candidate for the development of new drugs. Additionally, 5-Bromo-1H-quinolin-2-one has been investigated for its use as a fluorescent probe in biochemical and analytical studies. Overall, this compound has versatile properties that make it valuable in a range of chemical and biological applications.

Upstream product

• 4964-71-0 5-bromoquinoline 
• 349426-35-3 N-(3-bromophenyl)cinnamamide 
• 917341-34-5 (2E)-N-(3-bromophenyl)-3-phenylprop-2-enamide 
• 99465-18-6 (E)-N-(3-bromophenyl)-3-ethoxypropenamide 

Downstream Products

• 99455-13-7 5-bromo-2-chloroquinoline 
• 120258-64-2 2,5-dibromo-quinoline 
• 99455-06-8 5-bromo-2-methoxyquinoline 
• 99455-15-9 7-bromo-2-chloro-quinoline 
• 1404431-45-3 5-bromo-1-(4-methoxybenzyl)quinolin-2(1H)-one 
• 1404431-46-4 7-bromo-3-(4-methoxybenzyl)-3,7b-dihydro-1H-cyclopropa[c]quinolin-2(1aH)-one 
• 1219130-53-6 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolone 
• 347146-12-7 5-bromoquinolin-2-amine 

Relevant articles and documents

NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

The present invention relates to compounds of Formula (I) : and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.

2(1H)-Quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives

A series of (six-membered heteroaryl)-substituted 2(1H)-quinolinones was synthesized, and structure-activity relationships for cardiac stimulant activity were determined. Most compounds were prepared by acidic hydrolyisis of a heteroaryl-2-methoxyquinoline obtained by palladium-catalyzed cross-coupling methodology. Direct reaction of a pyridinylzinc reagent with a 6-haloquinolinone also proved successful. In anesthetized dogs, 6-pyridin-3-yl-2(1H)-quinolinone (3; 50 μg/kg) displayed greater inotropic activity (percentage increase in dP/dt max) than positional isomers, and potency was maintained with either mono- or di- alkylpyridinyl substituents. Introduction of a 4- or 7- methyl group into 3 reduced inotropic activity, whereas the 8-isomer proved to be the most potent member of the series. Compound 26 and the 2,6-dimethylpyridinyl analogue (27 were approximately 6 and 3 times more potent than milrinone. Several quinolinones displayed positive inotropic activity (decrease in QA interval) in conscious dogs after oral administration (1 mg/kg), and 26, 27 were again the most potent members of the series. Compound 27 (0.25, 0.5, 1.0 mg/kg po) demonstrated dose-related cardiac stimulant activity, which was maintained for at least 4 h. No changes in heart rate were observed. Compounds 3, 4, 26, and 27 also selectively stimulated the force of contraction, rather than heart rate, in the dog heart-lung preparation. For a 50% increase in dP/dt max with 27, heart rate changed by less than 10 beats/min. In norepinephrine contracted rabbit femoral artery and saphenous vein, 27 produced dose related (5 x 10-7 to 5 x 10-4 M) vasorelaxant activity. The combined cardiac stimulant and vasodilator properties displayed by 27, coupled with a lack of effect on heart rate, should be beneficial for the treatment of congestive heart failure.